Latest Insider Positions

Pierce David A is listed as an insider in the following companies: BSX / Boston Scientific Corp. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Peers of Pierce David A include the following: ABELE JOHN E, Ballinger Kevin J., Bose Supratim, Brennan Daniel J., Butcher Arthur C, Carruthers Wendy, Connors Nelda J, Dawkins Keith D, Dockendorff Charles J, FUJIMORI YOSHIAKI, Fitzgerald Joseph Michael, JAMES DONNA, JOHNSON KRISTINA M, LUDWIG EDWARD J, MACMILLAN STEPHEN P, MARIO ERNEST, Mackey Edward F, Mahoney Michael F, Meredith Ian T, Mirviss Jeffrey B., NICHOLAS NJ JR, NICHOLAS PETER M, Nanavaty Maulik, Phalen Michael P., Prange Karen, Pratt Timothy A., ROUX DAVID J, Ralls-Morrison Desiree, Sorenson John Bradley, Sununu John E, Thepaut Eric Francis Yves, Zane Ellen M, . Peers are determined by cross-linking the filings of Pierce David A with insider filings of others at the same companies.

Click the link icon to see the full transaction history.

Tran Date
Security Code Shares Post Shares Percent
2018-02-12 BSX / Boston Scientific SVP,Pres Urology,Pelvic Health F -8,238 40,487 -16.91 26.1800 -215,671
Open market or private purchase of non-derivative or derivative security
Open market or private sale of non-derivative or derivative security
Grant, award, or other acquisition of securities from the company (such as an option)
Conversion of derivative
Sale or transfer of securities back to the company
Payment of exercise price or tax liability using portion of securities received from the company
Gift of securities by or to the insider
Equity swaps and similar hedging transactions
Exercise or conversion of derivative security received from the company (such as an option)
A transaction voluntarily reported on Form 4
Other (accompanied by a footnote describing the transaction)

Related News Stories

Jana Takes New Stakes in Comcast, Facebook, GM; Drops Oracle - Bloomberg

2018-02-14 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (472-2)

NPPA cuts ceiling prices of stents further citing "larger public interest"

2018-02-12 moneycontrol
The National Pharmaceutical Pricing Authority (NPPA) on Monday further cut the ceiling prices of the most commonly used drug-eluting stent (DES) by 5.8 percent as it pursues the policy of price controls on coronary stents citing “larger public interest”. (34-0)

Hancock Jaffe Updates IPO Terms

2018-02-08 seekingalpha
Hancock Jaffe Laboratories (HJLI) intends to raise $7.7 million in a U.S. IPO, according to revised terms filed with the SEC. (37-0)

Cardiovascular Systems' (CSII) CEO Scott Ward on Q2 2018 Results - Earnings Call Transcript

2018-02-08 seekingalpha
Good afternoon. My name is Krista and I will be your conference operator today. At this time, I would like to welcome everyone to the Cardiovascular Systems, Inc. Fiscal Year 2018 Second Quarter Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] Thank you. (35-0)

Millipede to Aid Boston Scientific, LOTUS Relaunch Lag Ails

2018-02-07 zacks
On Feb 4, 2018, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX - Free Report) . The stock carries a Zacks Rank #3 (Hold). (91-0)

Boston Scientific's (BSX) CEO Michael Mahoney on Q4 2017 Results - Earnings Call Transcript

2018-02-02 seekingalpha
Ladies and gentlemen, thank you for standing by. Welcome to the Boston Scientific Fourth Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and answer-session. Instructions will be given at that time. [Operator Instructions] As a reminder, this conference is being recorded. (46-0)

Edwards Lifesciences (EW) CEO Michael Mussallem on Q4 2017 Results - Earnings Call Transcript

2018-02-02 seekingalpha
Greetings, and welcome to Edwards Lifesciences Fourth Quarter 2017 Results. At this time, all, participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder, this conference is being recorded. It is now my pleasure to introduce David Erickson, VP, Investor Relations. Thank you. Please begin. (75-0)

Boston Scientific (BSX) Q4 Earnings In Line, Revenues Top

2018-02-02 zacks
Boston Scientific Corporation (BSX - Free Report) posted adjusted earnings per share (EPS) of 34 cents in the fourth quarter of 2017, up 13.3% from the year-ago quarter. The figure remained in line with the Zacks Consensus Estimate and fell within the company's guided range of 32-35 cents for adjusted EPS. (44-0)

CORRECTED-UPDATE 1-Boston Scientific's sales beat, forecasts 2018 revenue above estimates

2018-02-01 reuters
(Reuters) - Boston Scientific Corp (BSX.N) on Thursday forecast better-than-expected 2018 revenue after the medical device maker’s fourth-quarter sales beat Wall Street estimates on higher sales in its cardiac rhythm management unit. (34-0)

Boston Scientific's (BSX) Q4 Earnings In Line, Sales Top

2018-02-01 zacks
MA-based Boston Scientific Corporation (BSX - Free Report) is a leading global manufacturer of medical devices that are used in a wide range of interventional medical specialties. Boston Scientific technologies address a wide range of health conditions through 7 business units that are organized into 3 global reporting segments: Rhythm Management, Cardiovascular and MedSurg. (55-0)